Viatris Total Current Assets 2010-2025 | VTRS
Viatris total current assets from 2010 to 2025. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
- Viatris total current assets for the quarter ending March 31, 2025 were $9.622B, a 25.54% decline year-over-year.
- Viatris total current assets for 2024 were $9.521B, a 26.63% decline from 2023.
- Viatris total current assets for 2023 were $12.976B, a 22.01% increase from 2022.
- Viatris total current assets for 2022 were $10.635B, a 2.45% decline from 2021.
| Viatris Annual Total Current Assets (Millions of US $) |
|
|---|---|
| 2024 | $9,521 |
| 2023 | $12,976 |
| 2022 | $10,635 |
| 2021 | $10,903 |
| 2020 | $12,868 |
| 2019 | $6,757 |
| 2018 | $6,368 |
| 2017 | $7,213 |
| 2016 | $7,523 |
| 2015 | $6,473 |
| 2014 | $6,441 |
| 2013 | $4,471 |
| 2012 | $3,903 |
| 2011 | $3,569 |
| 2010 | $3,559 |
| 2009 | $3,285 |
| Viatris Quarterly Total Current Assets (Millions of US $) |
|
|---|---|
| 2025-03-31 | $9,622 |
| 2024-12-31 | $9,521 |
| 2024-09-30 | $11,308 |
| 2024-06-30 | $11,792 |
| 2024-03-31 | $12,924 |
| 2023-12-31 | $12,976 |
| 2023-09-30 | $10,932 |
| 2023-06-30 | $9,778 |
| 2023-03-31 | $9,630 |
| 2022-12-31 | $10,635 |
| 2022-09-30 | $10,488 |
| 2022-06-30 | $11,177 |
| 2022-03-31 | $11,744 |
| 2021-12-31 | $10,903 |
| 2021-09-30 | $11,308 |
| 2021-06-30 | $11,750 |
| 2021-03-31 | $12,319 |
| 2020-12-31 | $12,868 |
| 2020-09-30 | $7,335 |
| 2020-06-30 | $6,465 |
| 2020-03-31 | $6,601 |
| 2019-12-31 | $6,757 |
| 2019-09-30 | $6,645 |
| 2019-06-30 | $6,265 |
| 2019-03-31 | $6,262 |
| 2018-12-31 | $6,368 |
| 2018-09-30 | $6,542 |
| 2018-06-30 | $6,298 |
| 2018-03-31 | $6,761 |
| 2017-12-31 | $7,213 |
| 2017-09-30 | $7,267 |
| 2017-06-30 | $6,966 |
| 2017-03-31 | $7,066 |
| 2016-12-31 | $7,523 |
| 2016-09-30 | $7,965 |
| 2016-06-30 | $12,187 |
| 2016-03-31 | $6,628 |
| 2015-12-31 | $6,473 |
| 2015-09-30 | $6,486 |
| 2015-06-30 | $7,891 |
| 2015-03-31 | $7,426 |
| 2014-12-31 | $6,441 |
| 2014-09-30 | $5,818 |
| 2014-06-30 | $4,477 |
| 2014-03-31 | $4,342 |
| 2013-12-31 | $4,471 |
| 2013-09-30 | $4,343 |
| 2013-06-30 | $4,212 |
| 2013-03-31 | $3,950 |
| 2012-12-31 | $3,903 |
| 2012-09-30 | $3,751 |
| 2012-06-30 | $3,752 |
| 2012-03-31 | $3,739 |
| 2011-12-31 | $3,569 |
| 2011-09-30 | $3,609 |
| 2011-06-30 | $3,760 |
| 2011-03-31 | $3,757 |
| 2010-12-31 | $3,559 |
| 2010-09-30 | $3,463 |
| 2010-06-30 | $3,629 |
| 2010-03-31 | $3,355 |
| 2009-12-31 | $3,285 |
| 2009-09-30 | $3,262 |
| 2009-06-30 | $3,023 |
| 2009-03-31 | $2,912 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.481B | $14.739B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $141.373B | 26.51 |
| Elevance Health (ELV) | United States | $87.880B | 11.34 |
| CVS Health (CVS) | United States | $87.261B | 10.85 |
| Cencora (COR) | United States | $58.118B | 20.22 |
| Natera (NTRA) | United States | $23.068B | 0.00 |
| DiDi Global (DIDIY) | China | $23.062B | 24.50 |
| Labcorp Holdings (LH) | United States | $21.972B | 17.82 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.845B | 0.00 |
| Solventum (SOLV) | United States | $13.121B | 13.89 |
| CochLear (CHEOY) | Australia | $12.902B | 0.00 |
| ICON (ICLR) | Ireland | $11.746B | 10.92 |
| Revvity (RVTY) | United States | $11.400B | 19.62 |
| Avantor (AVTR) | United States | $9.172B | 13.33 |
| HealthEquity (HQY) | United States | $9.059B | 39.68 |
| Medpace Holdings (MEDP) | United States | $9.021B | 23.96 |
| Sonic Healthcare (SKHHY) | Australia | $8.561B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.452B | 14.60 |
| Caris Life Sciences,�Inc (CAI) | $6.798B | 0.00 | |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.602B | 27.10 |
| BrightSpring Health Services (BTSG) | United States | $4.147B | 38.05 |
| Sotera Health (SHC) | United States | $3.156B | 17.93 |
| Surgery Partners (SGRY) | United States | $2.849B | 37.05 |
| Alignment Healthcare (ALHC) | United States | $2.770B | 0.00 |
| Concentras Parent (CON) | United States | $2.637B | 15.24 |
| GeneDx Holdings (WGS) | United States | $2.634B | 101.44 |
| Organon (OGN) | United States | $2.516B | 2.67 |
| PACS (PACS) | United States | $1.969B | 0.00 |
| Ardent Health (ARDT) | United States | $1.954B | 8.33 |
| Progyny (PGNY) | United States | $1.886B | 41.51 |
| Premier (PINC) | United States | $1.806B | 13.71 |
| GoodRx Holdings (GDRX) | United States | $1.779B | 35.57 |
| Teladoc Health (TDOC) | United States | $1.528B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.235B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.233B | 9.38 |
| CareDx (CDNA) | United States | $1.088B | 16.99 |
| Agilon Health (AGL) | United States | $0.952B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.919B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.840B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.791B | 7.41 |
| Nutex Health (NUTX) | United States | $0.692B | 10.47 |
| LifeMD (LFMD) | United States | $0.619B | 0.00 |
| Embecta (EMBC) | United States | $0.566B | 3.82 |
| InnovAge Holding (INNV) | United States | $0.498B | 0.00 |
| Enhabit (EHAB) | United States | $0.488B | 40.17 |
| SBC Medicals (SBC) | United States | $0.481B | 0.00 |
| Omada Health (OMDA) | $0.471B | 0.00 | |
| Sonida Senior Living (SNDA) | United States | $0.471B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.459B | 10.33 |
| So-Young (SY) | China | $0.314B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.313B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.262B | 0.00 |
| Beauty Health (SKIN) | United States | $0.241B | 0.00 |
| Oncology Institute (TOI) | United States | $0.183B | 0.00 |
| DocGo (DCGO) | United States | $0.160B | 26.17 |
| Pheton Holdings (PTHL) | China | $0.121B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.104B | 0.00 |
| KindlyMD (NAKA) | United States | $0.083B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.065B | 0.00 |
| NeueHealth (NEUE) | United States | $0.062B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.055B | 0.00 |
| ModivCare (MODV) | United States | $0.045B | 0.00 |
| Biodesix (BDSX) | United States | $0.041B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.034B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.033B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.027B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |